MX2022015606A - Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos. - Google Patents

Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.

Info

Publication number
MX2022015606A
MX2022015606A MX2022015606A MX2022015606A MX2022015606A MX 2022015606 A MX2022015606 A MX 2022015606A MX 2022015606 A MX2022015606 A MX 2022015606A MX 2022015606 A MX2022015606 A MX 2022015606A MX 2022015606 A MX2022015606 A MX 2022015606A
Authority
MX
Mexico
Prior art keywords
tablets
drug
processes
forming
immediate
Prior art date
Application number
MX2022015606A
Other languages
English (en)
Inventor
Sanjeev Kothari
Alexander Mauerer
Priscilla Mantik
Hamid Rezaei
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022015606A publication Critical patent/MX2022015606A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En términos generales, la presente descripción se refiere a comprimido de unidad de dosificación farmacéutica de liberación rápida que contienen un fármaco que es un inhibidor de la enzima de la proteína cinasa activadas por mitógenos, un relleno y un desintegrante, y a procesos para formar los comprimidos. Más específicamente, la presente descripción se refiere a comprimidos de unidad de dosificación farmacéutica que contienen cobimetinib, al menos un relleno, al menos un lubricante y al menos un desintegrante, y a métodos para preparar los comprimidos a partir de gránulos formados mediante granulación en seco.
MX2022015606A 2015-06-30 2017-12-13 Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos. MX2022015606A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562186556P 2015-06-30 2015-06-30

Publications (1)

Publication Number Publication Date
MX2022015606A true MX2022015606A (es) 2023-02-01

Family

ID=56373188

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017016163A MX2017016163A (es) 2015-06-30 2016-06-29 Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos.
MX2022015606A MX2022015606A (es) 2015-06-30 2017-12-13 Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.
MX2020013162A MX2020013162A (es) 2015-06-30 2017-12-13 Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017016163A MX2017016163A (es) 2015-06-30 2016-06-29 Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020013162A MX2020013162A (es) 2015-06-30 2017-12-13 Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.

Country Status (18)

Country Link
US (3) US10478400B2 (es)
EP (3) EP4272735A1 (es)
JP (3) JP6914202B2 (es)
KR (1) KR102716253B1 (es)
CN (2) CN108135854B (es)
AR (2) AR105184A1 (es)
AU (2) AU2016287422B2 (es)
BR (1) BR112017028218A2 (es)
CA (1) CA2987912C (es)
ES (2) ES2871175T3 (es)
HK (1) HK1254389A1 (es)
HR (2) HRP20240045T1 (es)
IL (2) IL256299B2 (es)
MX (3) MX2017016163A (es)
PL (2) PL3881833T3 (es)
SI (2) SI3881833T1 (es)
TW (3) TWI804919B (es)
WO (1) WO2017004122A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751288B2 (en) * 2016-08-23 2020-08-25 New Jersey Institute Of Technology Dry processed surface coated engineering excipients
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
BR112020006979A2 (pt) * 2017-10-13 2020-10-06 Unichem Laboratories Ltd composição farmacêutica estável, de liberação imediata para administração oral e processo para a preparação de composição farmacêutica estável, de liberação imediata, livre de desintegrante
CN110151763A (zh) * 2019-06-26 2019-08-23 深圳市第三人民医院 考比替尼作为制备治疗结核病药物中的应用
GB201913972D0 (en) 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture
BR112022024533A2 (pt) * 2020-06-19 2022-12-27 Glaxosmithkline Ip No 2 Ltd Formulação compreendendo daprodustat
JPWO2023145486A1 (es) * 2022-01-28 2023-08-03

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
CA2614468A1 (en) * 2005-07-15 2007-01-25 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
US8146000B1 (en) 2005-10-07 2012-03-27 Goodwell Technologies, Inc. Integrated transactional workflows distributed across multiple contact centers
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
WO2009120844A2 (en) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
CA2737528A1 (en) * 2008-09-17 2010-03-25 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
KR101429331B1 (ko) * 2009-06-22 2014-08-11 와이어쓰 엘엘씨 이부프로펜 나트륨 정제 및 이부프로펜 나트륨을 포함하는 제약 조성물의 제조 방법
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
AR086647A1 (es) * 2011-06-03 2014-01-15 Hoffmann La Roche Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k
WO2013082511A1 (en) * 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
KR20210033073A (ko) * 2011-12-27 2021-03-25 암젠 (유럽) 게엠베하 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
MX2014014831A (es) * 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
SG11201500582UA (en) * 2012-08-17 2015-04-29 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
PL2909188T3 (pl) 2012-10-12 2018-08-31 Exelixis, Inc. Nowy sposób wytwarzania związków do stosowania w leczeniu raka
ES2634020T3 (es) * 2013-03-06 2017-09-26 Novartis Ag Formulaciones de compuestos orgánicos
JP6568060B2 (ja) * 2013-07-12 2019-08-28 ピラマル エンタープライズイズ リミテッド 黒色腫の治療のための組合せ医薬
NZ715745A (en) * 2013-07-30 2017-06-30 Gilead Connecticut Inc Formulation of syk inhibitors
RU2018119749A (ru) * 2013-12-16 2018-11-09 Ф. Хоффманн-Ля Рош Аг Полиморфы 2-(4-(2-(1-изопропил-3-метил-1h-1,2,4-триазол-5-ил)-5,6-дигидробензо[f]имидазо[1,2-d][1,4]оксазепин-9-ил)-1h-пиразол-1-ил)-2-метилпропанамида, способы их получения и фармацевтические применения
AR105483A1 (es) * 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
EP4272735A1 (en) 2023-11-08
PL3316867T3 (pl) 2021-10-11
JP2021138716A (ja) 2021-09-16
HRP20240045T1 (hr) 2024-03-29
BR112017028218A2 (pt) 2018-08-28
TW201705944A (zh) 2017-02-16
WO2017004122A1 (en) 2017-01-05
CN108135854A (zh) 2018-06-08
AU2022201067A1 (en) 2022-03-10
ES2871175T3 (es) 2021-10-28
CN108135854B (zh) 2022-03-11
CA2987912C (en) 2023-01-24
US20220339111A1 (en) 2022-10-27
AR121624A2 (es) 2022-06-22
HRP20210828T1 (hr) 2021-07-09
US10478400B2 (en) 2019-11-19
HK1254389A1 (zh) 2019-07-19
CN114177157A (zh) 2022-03-15
AU2016287422B2 (en) 2021-11-18
EP3881833B1 (en) 2023-11-01
SI3881833T1 (sl) 2024-03-29
TW202337463A (zh) 2023-10-01
PL3881833T3 (pl) 2024-05-13
MX2017016163A (es) 2018-08-15
JP2023071769A (ja) 2023-05-23
CA2987912A1 (en) 2017-01-05
JP2018519305A (ja) 2018-07-19
KR102716253B1 (ko) 2024-10-11
ES2969014T3 (es) 2024-05-16
AU2016287422A1 (en) 2018-01-04
US20200085749A1 (en) 2020-03-19
TWI804919B (zh) 2023-06-11
EP3316867B1 (en) 2021-03-10
JP7232284B2 (ja) 2023-03-02
AR105184A1 (es) 2017-09-13
JP6914202B2 (ja) 2021-08-04
IL303352A (en) 2023-08-01
US20180116966A1 (en) 2018-05-03
TW202206068A (zh) 2022-02-16
EP3316867A1 (en) 2018-05-09
CN114177157B (zh) 2024-08-02
MX2020013162A (es) 2021-02-18
IL256299B2 (en) 2023-11-01
SI3316867T1 (sl) 2021-08-31
IL256299B1 (en) 2023-07-01
EP3881833A1 (en) 2021-09-22
IL256299A (en) 2018-02-28
TWI795344B (zh) 2023-03-11
KR20180021814A (ko) 2018-03-05

Similar Documents

Publication Publication Date Title
MX2020013162A (es) Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.
MX2017010858A (es) Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
EP4349406A3 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament
PH12016501841A1 (en) Immunosuppressant formulation
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
IN2014DN06966A (es)
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
EP3345600A4 (en) A MEGA-BASED TABLET, A METHOD FOR THE PRODUCTION OF A MIRABEGRAPHY-CONTAINING PHARMACEUTICAL PREPARATION, AND METHOD FOR THE PRODUCTION OF A MIRABEGRONOUS GRANULATED PRODUCT
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
EA201692479A1 (ru) Фармацевтическая композиция, которая содержит соединение пиразинкарбоксамида в качестве активного ингредиента
TR201722603A2 (tr) Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
IN2014MU00215A (es)
PH12015500469A1 (en) High dose extended-release potassium citrate wax matrix tablet
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.
PH12016502540A1 (en) Pharmaceutical dosage forms
EA201991269A1 (ru) Профилактический агент, агент, подавляющий начало заболевания, или терапевтический агент для прогрессирующих иммунных демиелинизирующих заболеваний
MX2018011685A (es) Proceso para formulaciones solidas de mesalazina.
WO2015114655A3 (en) Modified release tablet of pregabalin
MX2015011152A (es) Composicion farmaceutica de omeprazol-bicarbonato de sodio para integrar una capsula, para el tratamiento de alopatias relacionadas con la acidez gastrica.
UA91283U (uk) Фармацевтичний продукт, що має виражену антигестагенну дію
IN2014MU00665A (es)